A total of 320 stool specimens obtained from 262 patients suspected of having Clostridium diffciIe-associated gastrointestinal disease were examined with two cytotoxicity assays (CTAs) MATERIALS AND METHODS Specimens. Three hundred twenty unselected stool specimens obtained from 262 patients suspected of having CAD were examined over a 3-month period in 1991. Rectal swab specimens were excluded. Two hundred fifteen specimens were obtained from patients hospitalized at the UMMC. Of the remaining 105 specimens, 23 were obtained from UMMC outpatients and 82 were referred specimens submitted by community hospitals in central Massachusetts. All specimens were maintained at 4°C upon receipt in the laboratory and processed within 24 h of collection. At the time of processing, an aliquot of each specimen was frozen at -70°C. In selected instances, repeat testing was performed on this aliquot after it had been thawed to ca. 25°C.
laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease (CAD). These procedures include a latex agglutination test for a clostridial surface enzyme, glutamate dehydrogenase (17, 29) , enzyme immunoassays (EIAs) for toxins A and B (3, 15, 19, 20) , culture methods for C. difficile (10, 30, 36) , and cell culture cytotoxicity assays (CTAs) (5, 30, 36, 38) . In general, CTA has been regarded as the best single laboratory test for CAD. Recently, a commercial EIA in which both toxins A and B are detected by using monoclonal antibodies was approved by the Food and Drug Administration (FDA) . The Statistical analysis. Calculations of sensitivity, specificity, and positive and negative predictive values were accomplished as described by Galen and Gambino (9) . RESULTS A total of 320 stool specimens obtained from 262 patients were examined in this study. Among these, 244 specimens yielded negative results in all four C. difficile toxin assays and were considered true negatives. Forty-eight specimens were positive by all four assays and were considered truly positive for C. difficile. In the remaining 28 cated that 23 of these 28 specimens were in fact positive for C. difficile toxin; the other 5 were defined as negative (Table  1) . Collectively then, this study consisted of 249 negative and 71 positive stool samples, from 202 and 60 different patients, respectively.
The results obtained with all four C. difficile toxin assays are listed in Table 2 . The Bartels CTA detected all 71 positive stools but gave false-positive results in two cases. Conversely, the UMMC CTA yielded no false-positive results but gave false-negative results in two cases. The CBC EIA gave negative and indeterminant results with 10 and 3 of the 71 C. difficile-positive stools, respectively. Among the 249 C. difficile-negative specimens, 247 were negative and 2
were indeterminant by the CBC EIA. Twenty false-negative Table 3 . For the purposes of these calculations, the results of repeat tests on stools initially yielding indeterminant results were considered definitive.
Another approach to assessing the relative sensitivities of the four C. difficile toxin assays examined in this study was to compare the performance of these assays with the 23 stool specimens that were judged to be positive for C. difficile but which had yielded at least one discrepant result ( 18, 26) . High rates of asymptomatic carriage have been described in neonates (2, 7, 31) , patients with cystic fibrosis (28, 37) , and hospitalized patients who acquire their strains via nosocomial transmission (14, 22, 24, 26, 35) .
Direct detection of C. difficile toxin B, a potent cytotoxin, by cell culture assay is highly predictive in patients with characteristic epidemiology and clinical manifestations. The results of toxin B CTA, however, are dependent at least to some extent upon the cell line employed (23), the age of cells (33) , the manner in which the stool specimen was processed initially and the test format (36) . The sensitivity of CTA has been reported to vary between 67 and 78%; the specificity varies between 95 and 99% (12, 29, 30, 36 (27, 38) .
Alternative approaches to the diagnosis of CAD which have been developed recently include a commercially available latex agglutination test (29) and EIAs for direct application to stool samples (3, 15, 19, 20 (6, 12, 29, 30, 32) .
In 1988, the first enzyme immunoassay for C. difficile toxin became available commercially (Meridian Diagnostics). This is a monoclonal antibody-based assay for C. difficile toxin A. Estimates of the sensitivity of the Meridian EIA have ranged from 40 to 92%, whereas estimates of its specificity have ranged from 96 to 99.5% (1, 11, 34 (1:10) . Another possible explanation is the ability of the CBC EIA to detect C. difficile toxins A and B, rather than merely toxin A. There is good evidence that strains of C difficile are either completely nontoxigenic or produce both toxins A and B (8, 18) . If it is assumed that both toxins are produced in roughly equivalent amounts by toxigenic strains, then an EIA which detects both toxins A and B would be expected to be more sensitive than an EIA for toxin A only. This hypothesis is, of course, predicated on the assumption that the limit sensitivity of each assay (as determined by the smallest amount of toxin detectable) is comparable.
It should also be pointed out that nine specimens yielding false-negative results on initial testing with the Meridian EIA tested positive with this assay on repeat testing. The only salient difference between initial and repeat testing was that the second test was performed on stool that had been frozen at -70'C and thawed once. It is possible that freezing and thawing actually enhances the reactivity of the Meridian EIA.
In conclusion, the results of this study indicate that CTA is, in general, a more sensitive means for establishing a laboratory diagnosis of CAD than EIA. Of the two EIAs examined in this study, the CBC EIA was more sensitive than the Meridian EIA. Both assays yielded no false-positive results and thus, were 100% specific. Furthermore, the differences in sensitivities between the CTAs and the CBC EIA were relatively small. Although in this study, the CBC EIA missed 14% of the true-positive specimens, this assay merits consideration as a primary test for CAD, particularly in laboratories that lack the facilities and/or expertise to perform CTA.
